108 related articles for article (PubMed ID: 16253634)
1. Elevation of serum adiponectin levels in Basedow disease.
Saito T; Kawano T; Saito T; Ikoma A; Namai K; Tamemoto H; Kawakami M; Ishikawa SE
Metabolism; 2005 Nov; 54(11):1461-6. PubMed ID: 16253634
[TBL] [Abstract][Full Text] [Related]
2. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
3. [Maternal and cord blood thyroid hormones in Graves' disease and fetal states].
Koike S; Aoyama A; Yamaguchi N; Natori Y; Suzuki T; Itou M; Kusakabe K; Demura R
Rinsho Byori; 1993 Jun; 41(6):666-72. PubMed ID: 7689666
[TBL] [Abstract][Full Text] [Related]
4. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
5. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
6. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
7. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
[TBL] [Abstract][Full Text] [Related]
8. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.
Goh SY; Ho SC; Seah LL; Fong KS; Khoo DH
Clin Endocrinol (Oxf); 2004 May; 60(5):600-7. PubMed ID: 15104563
[TBL] [Abstract][Full Text] [Related]
9. [Spontaneous hypothyroidism in 4 patients with Graves-Basedow disease].
González-González A; Recio Cordova JM; Aznar Ondoño I; Del Monte Jarabo Bueno M
Endocrinol Nutr; 2009 May; 56(5):273-6. PubMed ID: 19627750
[TBL] [Abstract][Full Text] [Related]
10. Hyperthyroidism is associated with higher plasma endothelin-1 concentrations.
Chu CH; Lee JK; Keng HM; Chuang MJ; Lu CC; Wang MC; Sun CC; Wei MC; Lam HC
Exp Biol Med (Maywood); 2006 Jun; 231(6):1040-3. PubMed ID: 16741045
[TBL] [Abstract][Full Text] [Related]
11. Thyroid status and leptin in Basedow-Graves and multinodular goiter patients.
Seven R
J Toxicol Environ Health A; 2001 Aug; 63(8):575-81. PubMed ID: 11549117
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related?
Malyszko J; Malyszko J; Wolczynski S; Mysliwiec M
Nephrol Dial Transplant; 2006 Jan; 21(1):145-52. PubMed ID: 16141459
[TBL] [Abstract][Full Text] [Related]
13. Effect of experimental hypo- and hyperthyroidism on serum adiponectin.
Aragão CN; Souza LL; Cabanelas A; Oliveira KJ; Pazos-Moura CC
Metabolism; 2007 Jan; 56(1):6-11. PubMed ID: 17161219
[TBL] [Abstract][Full Text] [Related]
14. Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction.
Yaturu S; Prado S; Grimes SR
J Cell Biochem; 2004 Oct; 93(3):491-6. PubMed ID: 15372626
[TBL] [Abstract][Full Text] [Related]
15. Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Chu CH; Lee JK; Wang MC; Lu CC; Sun CC; Chuang MJ; Lam HC
Metabolism; 2008 Oct; 57(10):1380-3. PubMed ID: 18803942
[TBL] [Abstract][Full Text] [Related]
16. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.
Morishita E; Hashimoto T; Asakura H; Saito M; Yamazaki M; Aoshima K; Yoshida T; Kato H; Matsuda T
Thromb Haemost; 1998 May; 79(5):919-23. PubMed ID: 9609221
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
19. [Serum adiponectin levels in patients with acromegaly].
Siemińska L; Lenart J; Cichoń-Lenart A; Niedziołka D; Marek B; Kos-Kudła B; Kajdaniuk D; Nowak M
Pol Merkur Lekarski; 2005 Oct; 19(112):514-6. PubMed ID: 16379314
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
